Alliancebernstein L.P. raised its position in shares of Sanofi SA (NYSE:SNY) by 617.8% in the third quarter, Holdings Channel reports. The fund owned 306,090 shares of the company’s stock after acquiring an additional 263,445 shares during the quarter. Alliancebernstein L.P.’s holdings in Sanofi were worth $13,673,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Institute for Wealth Management LLC. grew its position in shares of Sanofi by 27.4% in the second quarter. Institute for Wealth Management LLC. now owns 31,936 shares of the company’s stock valued at $1,278,000 after purchasing an additional 6,860 shares in the last quarter. Van ECK Associates Corp grew its position in shares of Sanofi by 15.1% in the second quarter. Van ECK Associates Corp now owns 361,195 shares of the company’s stock valued at $14,451,000 after purchasing an additional 47,420 shares in the last quarter. Alpha Cubed Investments LLC purchased a new stake in shares of Sanofi in the third quarter valued at approximately $233,000. Usca Ria LLC grew its position in shares of Sanofi by 20.9% in the third quarter. Usca Ria LLC now owns 13,895 shares of the company’s stock valued at $621,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Nomura Holdings Inc. grew its position in shares of Sanofi by 51.8% in the second quarter. Nomura Holdings Inc. now owns 50,726 shares of the company’s stock valued at $2,030,000 after purchasing an additional 17,310 shares in the last quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

SNY has been the subject of a number of analyst reports. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Friday, November 30th. Guggenheim initiated coverage on Sanofi in a research report on Monday, October 8th. They issued a “neutral” rating for the company. ValuEngine upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, October 15th. Finally, Wolfe Research initiated coverage on Sanofi in a research report on Tuesday, October 23rd. They issued a “market perform” rating for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $49.50.

Shares of Sanofi stock opened at $43.71 on Friday. The company has a market capitalization of $110.71 billion, a P/E ratio of 13.96, a price-to-earnings-growth ratio of 2.50 and a beta of 0.71. Sanofi SA has a fifty-two week low of $37.43 and a fifty-two week high of $45.86. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Wednesday, October 31st. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.09. The company had revenue of $9.39 billion during the quarter, compared to analyst estimates of $9.10 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.71 earnings per share. Equities research analysts predict that Sanofi SA will post 3.09 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/sanofi-sa-sny-shares-bought-by-alliancebernstein-l-p/2666429.html.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: How dollar cost averaging works

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.